GlobeNewswire Inc.··NaMadrigal Pharma to Report Q1 2026 Results as Rezdiffra Ramps Up Commercial Launch
Madrigal Pharmaceuticals reports Q1 2026 results May 6, revealing early commercial performance of FDA/EMA-approved MASH treatment Rezdiffra following recent regulatory clearances.
MDGLfinancial resultsFDA approval